Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Chemical signatures and new drug targets for gametocytocidal drug development.

Sun W, Tanaka TQ, Magle CT, Huang W, Southall N, Huang R, Dehdashti SJ, McKew JC, Williamson KC, Zheng W.

Sci Rep. 2014 Jan 17;4:3743. doi: 10.1038/srep03743.

2.

Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease.

Ottinger EA, Kao ML, Carrillo-Carrasco N, Yanjanin N, Shankar RK, Janssen M, Brewster M, Scott I, Xu X, Cradock J, Terse P, Dehdashti SJ, Marugan J, Zheng W, Portilla L, Hubbs A, Pavan WJ, Heiss J, Vite CH, Walkley SU, Ory DS, Silber SA, Porter FD, Austin CP, McKew JC.

Curr Top Med Chem. 2014;14(3):330-9. Review.

3.

Structure-activity relationship of imidazopyridinium analogues as antagonists of neuropeptide s receptor.

Patnaik S, Marugan JJ, Liu K, Zheng W, Southall N, Dehdashti SJ, Thorsell A, Heilig M, Bell L, Zook M, Eskay B, Brimacombe KR, Austin CP.

J Med Chem. 2013 Nov 27;56(22):9045-56. doi: 10.1021/jm400904m. Epub 2013 Nov 11.

4.

A phenotypic compound screening assay for lysosomal storage diseases.

Xu M, Liu K, Swaroop M, Sun W, Dehdashti SJ, McKew JC, Zheng W.

J Biomol Screen. 2014 Jan;19(1):168-75. doi: 10.1177/1087057113501197. Epub 2013 Aug 27.

5.

A high-throughput screening assay for determining cellular levels of total tau protein.

Dehdashti SJ, Zheng W, Gever JR, Wilhelm R, Nguyen DT, Sittampalam G, McKew JC, Austin CP, Prusiner SB.

Curr Alzheimer Res. 2013 Sep;10(7):679-87.

6.

A high-throughput screening assay for assessing the viability of Cryptococcus neoformans under nutrient starvation conditions.

Dehdashti SJ, Abbott J, Nguyen DT, McKew JC, Williamson PR, Zheng W.

Anal Bioanal Chem. 2013 Aug;405(21):6823-9. doi: 10.1007/s00216-013-7134-4. Epub 2013 Jun 30.

7.

A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats.

Thorsell A, Tapocik JD, Liu K, Zook M, Bell L, Flanigan M, Patnaik S, Marugan J, Damadzic R, Dehdashti SJ, Schwandt ML, Southall N, Austin CP, Eskay R, Ciccocioppo R, Zheng W, Heilig M.

J Neurosci. 2013 Jun 12;33(24):10132-42. doi: 10.1523/JNEUROSCI.4742-12.2013.

8.

A quantitative high throughput assay for identifying gametocytocidal compounds.

Tanaka TQ, Dehdashti SJ, Nguyen DT, McKew JC, Zheng W, Williamson KC.

Mol Biochem Parasitol. 2013 Mar;188(1):20-5. doi: 10.1016/j.molbiopara.2013.02.005. Epub 2013 Feb 27.

9.

Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.

Cunningham L, Finckbeiner S, Hyde RK, Southall N, Marugan J, Yedavalli VR, Dehdashti SJ, Reinhold WC, Alemu L, Zhao L, Yeh JR, Sood R, Pommier Y, Austin CP, Jeang KT, Zheng W, Liu P.

Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14592-7. doi: 10.1073/pnas.1200037109. Epub 2012 Aug 21.

10.

Identification of a selective small-molecule inhibitor series targeting the eyes absent 2 (Eya2) phosphatase activity.

Krueger AB, Dehdashti SJ, Southall N, Marugan JJ, Ferrer M, Li X, Ford HL, Zheng W, Zhao R.

J Biomol Screen. 2013 Jan;18(1):85-96. doi: 10.1177/1087057112453936. Epub 2012 Jul 20.

11.

Effect of mutations in the T1.5 loop of pectate lyase A from Erwinia chrysanthemi EC16.

Dehdashti SJ, Doan CN, Chao KL, Yoder MD.

Acta Crystallogr D Biol Crystallogr. 2003 Jul;59(Pt 7):1339-42. Epub 2003 Jun 27.

PMID:
12832805

Supplemental Content

Loading ...
Support Center